verapamil hci

Generic: verapamil hci

Labeler: hf acquisition co llc, dba healthfirst
NDC Directory HUMAN PRESCRIPTION DRUG ANDA Inactive Finished

Drug Facts

Product Profile

Brand Name verapamil hci
Generic Name verapamil hci
Labeler hf acquisition co llc, dba healthfirst
Dosage Form INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients

verapamil hydrochloride 2.5 mg/mL

Manufacturer
HF Acquisition Co LLC, DBA HealthFirst

Identifiers & Regulatory

Product NDC 51662-1548
Product ID 51662-1548_df7a677c-e654-5f4b-e053-2995a90a06b3
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category ANDA
Application Number ANDA212965
Listing Expiration 2026-12-31
Marketing Start 2022-05-20

Pharmacologic Class

Classes
calcium channel antagonists [moa] calcium channel blocker [epc] cytochrome p450 3a inhibitors [moa] cytochrome p450 3a4 inhibitors [moa] p-glycoprotein inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 516621548
Hyphenated Format 51662-1548

Supplemental Identifiers

RxCUI
1665061
UPC
0355150343010
UNII
V3888OEY5R

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name verapamil hci (source: ndc)
Generic Name verapamil hci (source: ndc)
Application Number ANDA212965 (source: ndc)
Routes
INTRAVENOUS
source: ndc

Resolved Composition

Strengths
  • 2.5 mg/mL
source: ndc
Packaging
  • 4 mL in 1 VIAL, SINGLE-DOSE (51662-1548-1)
source: ndc

Packages (1)

Ingredients (1)

verapamil hydrochloride (2.5 mg/mL)

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["INTRAVENOUS"], "spl_id": "df7a677c-e654-5f4b-e053-2995a90a06b3", "openfda": {"upc": ["0355150343010"], "unii": ["V3888OEY5R"], "rxcui": ["1665061"], "spl_set_id": ["df786377-7d2c-249b-e053-2a95a90aab22"], "manufacturer_name": ["HF Acquisition Co LLC, DBA HealthFirst"]}, "finished": true, "packaging": [{"sample": false, "description": "4 mL in 1 VIAL, SINGLE-DOSE (51662-1548-1)", "package_ndc": "51662-1548-1", "marketing_start_date": "20220520"}], "brand_name": "VERAPAMIL HCI", "product_id": "51662-1548_df7a677c-e654-5f4b-e053-2995a90a06b3", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Calcium Channel Antagonists [MoA]", "Calcium Channel Blocker [EPC]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "51662-1548", "generic_name": "VERAPAMIL HCI", "labeler_name": "HF Acquisition Co LLC, DBA HealthFirst", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "VERAPAMIL HCI", "active_ingredients": [{"name": "VERAPAMIL HYDROCHLORIDE", "strength": "2.5 mg/mL"}], "application_number": "ANDA212965", "marketing_category": "ANDA", "marketing_start_date": "20220520", "listing_expiration_date": "20261231"}